Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Inozyme Pharma Inc (INZY)

Inozyme Pharma Inc (INZY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.1200 (unch)
ARVN : 36.15 (-2.98%)
NXTC : 1.8300 (+7.65%)
BHVN : 18.09 (-2.53%)
INZY : 2.62 (unch)
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

AZN : 64.36 (+0.11%)
SRNE : 0.9835 (-6.33%)
PLRX : 31.74 (-1.67%)
INZY : 2.62 (unch)
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

BLUE : 6.24 (-6.73%)
RYTM : 27.93 (-5.42%)
PLRX : 31.74 (-1.67%)
INZY : 2.62 (unch)
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

AGLE : 0.5657 (+12.85%)
RYTM : 27.93 (-5.42%)
PLRX : 31.74 (-1.67%)
INZY : 2.62 (unch)
bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia

bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.

BLUE : 6.24 (-6.73%)
STRO : 6.73 (-3.86%)
IMVT : 18.66 (-1.79%)
INZY : 2.62 (unch)
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study

Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.

STRO : 6.73 (-3.86%)
ARTL : 3.04 (+1.33%)
IMVT : 18.66 (-1.79%)
INZY : 2.62 (unch)
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

BMRN : 110.44 (-0.78%)
EPZM : 1.4700 (-1.34%)
APTX : 0.6000 (-12.47%)
INZY : 2.62 (unch)
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...

INZY : 2.62 (unch)
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose cohort (0.2 mg/kg) – - INZ-701 was...

INZY : 2.62 (unch)
How Much Upside is Left in Inozyme Pharma, Inc. (INZY)? Wall Street Analysts Think 309%

The consensus price target hints at a 308.5% upside potential for Inozyme Pharma, Inc. (INZY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

INZY : 2.62 (unch)

Barchart Exclusives

Here’s a Big Reason to Like Simon Property Group Other Than Real Estate
Retail REIT Simon Property Group reported stronger-than-expected Q4 2022 results on Monday. But, looking ahead, it sees lower cash flow in 2023. Despite the cloudy profit picture, there’s a big reason to like SPG stock beyond real estate. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar